Published in Swiss Med Wkly on June 06, 2013
Metabolomics: Applications and Promise in Mycobacterial Disease. Ann Am Thorac Soc (2015) 1.96
Effects of pre-analytical processes on blood samples used in metabolomics studies. Anal Bioanal Chem (2015) 0.91
Sparse Proteomics Analysis - a compressed sensing-based approach for feature selection and classification of high-dimensional proteomics mass spectrometry data. BMC Bioinformatics (2017) 0.88
Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. J Proteome Res (2014) 0.83
Metabolomics profiling for identification of novel potential markers in early prediction of preeclampsia. PLoS One (2014) 0.83
Does centrifugation matter? Centrifugal force and spinning time alter the plasma metabolome. Metabolomics (2016) 0.82
Deciphering the ovarian cancer ascites fluid peptidome. Clin Proteomics (2014) 0.78
Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med (2008) 12.41
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol (2009) 3.28
Lead poisoning due to adulterated marijuana in leipzig. Dtsch Arztebl Int (2008) 2.72
Angiogenesis and hepatocellular carcinoma. J Hepatol (2004) 2.25
New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. Clin Chem (2005) 2.24
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J Hepatol (2012) 2.07
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis (2013) 1.85
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol (2007) 1.56
Sepsis-associated changes of the arachidonic acid metabolism and their diagnostic potential in septic patients. Crit Care Med (2012) 1.56
Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem (2005) 1.48
Dietary intervention to reverse carotid atherosclerosis. Circulation (2010) 1.28
Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther (2008) 1.24
Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin Sci (Lond) (2009) 1.22
Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol (2011) 1.19
Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol (2005) 1.17
Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics (2011) 1.17
Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg (2002) 1.16
The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci (2004) 1.14
Regulation of Ca(2+) signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. Hepatology (2002) 1.11
Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol (2008) 1.10
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
Treatment of NASH with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol (2012) 1.06
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther (2011) 1.06
Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry. Clin Chim Acta (2004) 1.02
Challenges and developments in tandem mass spectrometry based clinical metabolomics. Mol Cell Endocrinol (2008) 1.00
Rapid quantification of free and esterified phytosterols in human serum using APPI-LC-MS/MS. J Lipid Res (2004) 0.99
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS One (2013) 0.97
Hit proteins, mitochondria and cancer. Biochim Biophys Acta (2011) 0.95
Dairy calcium intake, serum vitamin D, and successful weight loss. Am J Clin Nutr (2010) 0.95
Extended preservation of rat liver graft by induction of heme oxygenase-1. Hepatology (2002) 0.95
Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology (2006) 0.94
Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int (2007) 0.94
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. Liver Int (2014) 0.93
Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int (2007) 0.92
Disruption of the histidine triad nucleotide-binding hint2 gene in mice affects glycemic control and mitochondrial function. Hepatology (2013) 0.91
Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int (2009) 0.90
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology (2012) 0.90
Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol (2004) 0.89
Expression and regulation of gap junctions in rat cholangiocytes. Hepatology (2002) 0.88
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. J Hepatol (2013) 0.87
[Non-alcoholic steatohepatitis - from NAFLD to MAFLD]. Ther Umsch (2011) 0.87
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients. Liver Int (2013) 0.86
Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol (2013) 0.86
Liver surgery in the era of tissue-preserving resections: early and late outcome in patients with primary and secondary hepatic tumors. World J Surg (2002) 0.85
Hint2 is expressed in the mitochondria of H295R cells and is involved in steroidogenesis. Endocrinology (2008) 0.85
Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases. Med Hypotheses (2004) 0.85
Hyperkalemia in the emergency department: etiology, symptoms and outcome of a life threatening electrolyte disorder. Eur J Intern Med (2013) 0.84
Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma. Clin Sci (Lond) (2014) 0.84
Ablation of the tumor suppressor histidine triad nucleotide binding protein 1 is protective against hepatic ischemia/reperfusion injury. Hepatology (2010) 0.83
Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond) (2010) 0.83
Potential of dried blood self-sampling for cyclosporine c(2) monitoring in transplant outpatients. J Transplant (2010) 0.83
Thyroid function and serum electrolytes: does an association really exist? Swiss Med Wkly (2012) 0.82
Standardized peptidome profiling of human cerebrospinal fluid by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Proteomics (2008) 0.82
Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver. J Hepatol (2007) 0.82
Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss Med Wkly (2008) 0.82
Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics (2012) 0.82
Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med Wkly (2002) 0.82
Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. J Drug Target (2007) 0.82
Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities. Clin Sci (Lond) (2014) 0.81
UDCA for NASH: end of the story? J Hepatol (2010) 0.81
Hepatocellular carcinoma in a non-cirrhotic patient with Wilson's disease. World J Gastroenterol (2013) 0.80
TACE with or without systemic therapy? J Hepatol (2012) 0.79
Disproportionally high results of transient elastography in patients with autoimmune hepatitis. Liver Int (2008) 0.79
Modern hepatomancy. Gastroenterology (2013) 0.79
PI(3)K/PTEN/AKT pathway. J Hepatol (2010) 0.79
Vasopressin type 1A receptor up-regulation by cyclosporin A in vascular smooth muscle cells is mediated by superoxide. J Biol Chem (2003) 0.78
Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition. Hepatology (2005) 0.78
Autoimmune hemolytic anemia: classification and therapeutic approaches. Expert Rev Hematol (2008) 0.78
Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol (2006) 0.78
C-reactive protein, a prognostic marker in hepatocellular carcinoma. Hepatology (2013) 0.78
NASH and thiazolidinediones: not to be taken lightly. J Hepatol (2007) 0.78
Congenital dyserythropoietic anaemia type II (HEMPAS) and haemochromatosis: a report of two cases. Eur J Gastroenterol Hepatol (2003) 0.78
Diagnostic significance of high sensitivity troponin in diagnosis of blunt cardiac injury. Intensive Care Med (2014) 0.78
Characterization of the effect of the mitochondrial protein Hint2 on intracellular Ca(2+) dynamics. Biophys J (2013) 0.77
Targeting vessels to treat hepatocellular carcinoma. Clin Sci (Lond) (2008) 0.77
Acute ophthalmoparesis associated with human parvovirus B19 infection. Eur J Ophthalmol (2011) 0.76
Dietary intervention induces flow of changes within biomarkers of lipids, inflammation, liver enzymes, and glycemic control. Nutrition (2011) 0.76
Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. Swiss Med Wkly (2003) 0.76
Bridging hyperacute liver failure by ABO-incompatible auxiliary partial orthotopic liver transplantation. Transpl Int (2007) 0.76
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. Swiss Med Wkly (2012) 0.76
The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. Clin Liver Dis (2013) 0.76
High-Sensitive Troponin Measurement in Emergency Department Patients Presenting with Syncope: A Retrospective Analysis. PLoS One (2013) 0.75
[Liver transplantation - when and for whom it should be performed]. Ther Umsch (2011) 0.75
Abnormal nitrosothiol metabolism in hepatocellular carcinoma. J Hepatol (2010) 0.75
Liver allocation in Switzerland. Liver Transpl (2002) 0.75
Cholestasis shuts down calcium signaling in cholangiocytes. Hepatology (2004) 0.75
Treat the bones and get less rejection! Liver Int (2009) 0.75
Treatment of Non-Alcoholic Fatty Liver Disease. Dig Dis (2016) 0.75
Hepatology Highlights. Hepatology (2017) 0.75
Hepatology Highlights. Hepatology (2017) 0.75
Hepatology Highlights. Hepatology (2017) 0.75
Hepatology Highlights. Hepatology (2016) 0.75
Hepatology Highlights. Hepatology (2017) 0.75
Hepatology Highlights. Hepatology (2016) 0.75
Hepatology Highlights. Hepatology (2016) 0.75